Document is current

Article History

Received: 6 February 2023

Accepted: 1 August 2023

First Online: 24 August 2023

Declarations

:

: Megan L Neely, Anne S Hellkamp, Jamie L Todd and Scott M Palmer are employees of the Duke Clinical Research Institute (DCRI), which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) to coordinate the IPF-PRO/ILD-PRO Registry. Jamie L Todd reports grants paid to her institution from AstraZeneca and CareDx and has participated on advisory boards for Altavant Sciences, Natera, Sanofi, Theravance. Scott M Palmer reports research funding paid to DCRI from Bristol-Myers Squibb and Genentech and has participated on advisory boards for Altavant and Bristol-Myers Squibb. Shaun Bender was an employee of BIPI at the time that this study was conducted. Timothy Liesching, Justin M Oldham, Tracy R Luckhardt and Rishi Raj are principal investigators at enrolling centres for the IPF-PRO Registry. Tracy R Luckhardt serves on the IPF-PRO/ILD-PRO Registry Biomarker Committee. Justin M Oldham serves on the IPF-PRO/ILD-PRO Registry Publication Committee. Rishi Raj reports an investigator-initiated research grant from and has served on an advisory board for BI. Eric S White is an employee of BIPI.

: The study was approved by the Duke University Institutional Review Board (Pro00046131). The protocol was approved by the relevant Institutional Review Boards and/or local Independent Ethics Committees prior to patient enrolment at each site listed in the Acknowledgments. All patients provided informed consent.

: Not applicable.